BioCentury
ARTICLE | Clinical News

NovaBay falls on impetigo miss

November 7, 2013 1:36 AM UTC

NovaBay Pharmaceuticals Inc. (NYSE-M:NBY) said a topical gel formulation of the company's auriclosene ( NVC-422) missed the primary endpoint in a Phase IIb trial to treat impetigo. NovaBay and partner Galderma S.A. (Lausanne, Switzerland) could not be reached for details, but said they are analyzing the data to determine next steps. Galderma has exclusive, worldwide rights to develop and commercialize NovaBay's Aganocide compounds, including auriclosene, for impetigo, acne and other dermatological indications. Auriclosene is a synthetic analog of the phagocytosis-associated compound N, N-dichlorotaurine (NNDCT). ...